Clinical trials: Relapsed Refractory Multiple Myeloma
Healthy Volunteers, Relapsed Multiple Myeloma
A Clinical Study to Evaluate the Effects of RO7875913 in Healthy Participants and of RO7875913 With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma
Part A: The purpose of Part A of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of RO7875913 in healthy participants.
- Conditions
- Healthy Volunteers, Relapsed Multiple Myeloma, Refractory Multiple Myeloma
- Trial name
- NCT07342114
- Testing
- RO7875913, Cevostamab
- Where
- New Zealand
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Relapsed Multiple Myeloma, Refractory Multiple Myeloma
Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma
The food and drug administration (FDA) has approved the use of Selinexor, an oral, first-in class, exportin 1 (XPO1) inhibitor, in combination with low-dose dexamethasone in patients with triple-refractory (disease refractory to…
- Trial name
- ESdRRMM (NCT05170789)
- Testing
- Elotuzumab, Selinexor, and Dexamethasone (ESd)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Tulane University School of Medicine